Equities

SyntheticMR AB (publ)

SyntheticMR AB (publ)

Actions
  • Price (SEK)12.00
  • Today's Change0.10 / 0.84%
  • Shares traded20.65k
  • 1 Year change-45.45%
  • Beta0.7819
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SyntheticMR AB (publ) is a Sweden-based company that develops and markets software solutions for Magnetic Resonance Imaging (MRI). The Company provides SyMRI, which measures the absolute properties of the brain and delivers adjustable contrast images, automatic biomarker segmentation and quantitative data in a single MR scan. The SyMRI product is available in different packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps, parametric common contrast weighted images and maps of the brain, allowing the investigation to be taken even further. SyMRI is a registered trademark in Europe and in the USA.

  • Revenue in SEK (TTM)81.53m
  • Net income in SEK4.72m
  • Incorporated2007
  • Employees43.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nexstim Oyj89.91m-9.46m285.72m39.00--13.48--3.18-0.1223-0.12231.190.27610.81960.22235.28214,040.30-8.62-26.77-14.02-43.9097.2492.11-10.52-38.381.24-5.510.7716---23.9422.08-201.58--19.51--
INIFY Laboratories AB3.42m-51.44m304.55m23.00--4.16--88.99-1.18-1.180.07851.680.0322.990.6608---48.10---48.10--76.42---1,503.10------0.00--------------
Micropos Medical AB (publ)2.68m-22.68m305.25m9.00--14.92--113.86-0.2463-0.24630.0220.13410.09940.13151.20335,122.50-84.10-64.24-111.33-82.2779.96114.76-845.91-767.573.18--0.0184--50.235.94-26.57------
Ortoma AB43.22m-30.78m322.32m7.00--1.95--7.46-0.8112-0.81121.244.670.22941.014.496,173,962.00-16.34-10.45-17.53-11.6486.83339.86-71.22-175.523.04--0.00-------38.87--14.14--
Acarix AB6.26m-70.95m326.01m9.00--4.81--52.10-0.1168-0.11680.00950.06970.08940.11722.47---101.38-66.93-123.43-77.1288.2779.42-1,133.87-1,483.685.21-328.980.00--7.2043.55-1.11------
Karolinska Development AB1.90m-5.65m337.08m8.00--0.2762--177.13-0.0209-0.02090.0074.560.0015--1.38237,875.00-0.45363.37-0.45783.83-----296.851,466.36----0.00210.00-12.43-8.10106.11-29.31----
Boule Diagnostics AB572.53m21.28m338.62m230.0016.240.68247.140.59150.53680.536814.4512.780.7244.193.692,511,092.002.681.673.712.4043.8643.503.702.040.92684.720.269842.244.246.1396.24-9.45-9.74--
Q linea AB4.70m-224.61m362.04m99.00--5.32--77.11-2.06-2.060.04280.58130.02770.170711.8636,968.50-132.70-59.66-356.93-66.14-56.25-378.58-4,783.96-4,046.970.6999--0.4555---65.2833.0214.64--41.94--
ContextVision AB132.40m25.69m428.60m41.0016.684.7712.453.240.34450.34451.781.211.212.334.813,433,738.0023.3929.3930.6743.2797.3998.5819.4027.153.99--0.0304--12.197.78-1.77---35.88--
BrainCool AB (publ)32.23m-57.17m483.47m20.00--2.92--15.00-0.2685-0.26850.15010.65270.22532.042.851,343,042.00-39.96-47.14-44.79-70.16-37.24-149.77-177.38-391.454.16-6.190.00--32.0678.35-34.34---11.63--
SyntheticMR AB (publ)81.53m4.72m496.09m43.00104.944.3843.726.080.11340.11341.962.720.6049--1.532,203,514.003.507.194.248.8570.2769.705.799.08--18.000.006621.5030.6713.0570.34-7.3327.30--
Integrum AB102.18m-2.52m525.19m36.00--2.92692.935.14-0.1244-0.12445.299.580.57060.56663.592,620,068.00-1.41-1.71-1.55-1.9887.2583.87-2.47-2.875.54-0.66360.0325--40.1935.91124.92--127.10--
Modulight Oyj39.15m-134.54m541.86m79.00--0.9185--13.84-0.2844-0.28440.08361.220.0516-0.31111.9449,271.43-17.72-8.39-18.97-9.10123.49114.69-343.58-56.814.50--0.0965---12.48-8.20-38.69--63.60--
Bioretec Oy46.27m-40.08m618.74m43.00--8.43--13.37-0.1752-0.17520.20240.3180.41041.233.75110,166.80-35.54-66.83-40.92-97.1969.9770.97-86.61-133.494.04--0.0696--32.7819.77-54.02------
Senzime AB (publ)47.04m-130.32m640.61m52.00--2.39--13.62-1.16-1.160.41522.670.12791.444.39---35.42-35.69-37.96-38.0029.89-20.59-277.04-558.683.61--0.07--154.7761.90-1.09---3.69--
Data as of Sep 13 2024. Currency figures normalised to SyntheticMR AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 30 Aug 20241.94m0.00%
Handelsbanken Fonder ABas of 31 Aug 20241.88m0.00%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 28 Mar 20241.63m0.00%
Aktia Bank Plc (Investment Management)as of 28 Mar 2024915.34k0.00%
Fondita Fund Management Co. Ltd.as of 31 Jul 2024500.00k0.00%
Seven Canyons Advisors LLCas of 30 Jun 2024120.40k0.00%
Nordea Investment Management AB (Finland)as of 31 Jul 202483.47k0.00%
Axxion SA (Luxembourg)as of 31 Jul 202460.27k0.00%
More ▼
Data from 28 Jun 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.